1.1

1.23

## SENATE STATE OF MINNESOTA NINETY-FIRST SESSION

A Senate resolution

S.F. No. 4484

(SENATE AUTHORS: WESTROM and Koran)

DATE D-PG OFFICIAL STATUS
04/16/2020 5627 Introduction and first reading

Referred to Health and Human Services Finance and Policy 04/23/2020 5837 Author added Koran

memorializing the President and Congress to direct the United States Food and Drug 1.2 Administration to approve off-label use of certain medications to combat COVID-19. 1.3 WHEREAS, COVID-19 is a respiratory disease caused by a coronavirus called SARS-CoV-2; 1.4 and 1.5 WHEREAS, the number of cases of COVID-19 being reported in the United States is 1.6 increasing, reflecting the rapid spread of the disease; and 1.7 WHEREAS, the duration and severity of the symptoms of COVID-19 vary, ranging from 1.8 very mild to severe, including death; and 1.9 WHEREAS, currently there are no drugs or other therapeutics approved by the United States 1.10 Food and Drug Administration to treat COVID-19; and 1.11 WHEREAS, currently there are no vaccines available for COVID-19; and 1.12 WHEREAS, there have been multiple reports that the off-label use of hydroxychloroguine 1.13 with azithromycin to treat COVID-19 results in milder symptoms and quicker recoveries, and in 1.14 some cases has prevented death; NOW, THEREFORE, 1.15 BE IT RESOLVED by the legislature of the state of Minnesota that it urges the President 1.16 and Congress of the United States to direct the United States Food and Drug Administration to 1.17 expedite the approval and permit the off-label use of hydroxychloroquine, chloroquine, ivermectin, 1.18 1.19 remdesivir, and other medications that show promise in combating COVID-19 by patients who 1.20 have been diagnosed with COVID-19. BE IT FURTHER RESOLVED that the Secretary of the Senate is directed to prepare copies 1.21 of this memorial and transmit them to the President of the United States, the President and Secretary 1.22

of the United States Senate, the Speaker and the Clerk of the United States House of Representatives,

04/15/20 REVISOR EM/HR 20-8385 as introduced

2.1 the chair of the United States Senate Committee on Finance, the chair of the United States House

2.2 Committee on Ways and Means, and Minnesota's senators and representatives in Congress.